Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesLandmark study for GSK's cervical cancer vaccine published in The Lancet
GlaxoSmithKline, 07/08/09
The final analysis of the largest efficacy trial of a cervical cancer vaccine is published in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix is highly effective at protecting against the two most common cervical cancer-causing human papillomavirus types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types beyond 16 and 18.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
First-in-Human Study Demonstrating Pharmacological Activation of Heme Oxygenase-1 in Humans
Clinical Pharmacology & Therapeutics, 12/08/09
Amgen Presents Data From First Nplate Study in Children With Chronic ITP
Amgen, 12/08/09
Sponsor
Article Search
Sponsor